Nuzenio

Obesity Drug Into

Obesity Drug Into news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Eli Lilly (NYSE: LLY) Files For Next-Gen Weight-Loss Drug Retatrutide In Q1 2027, Leaving Novo Nordisk (NYSE: NVO) Scrambling - foreignpolicyjournal.comforeignpolicyjournal.com · Mon, 10 Aug 2026 00:24:00 GMT Structure Therapeutics (GPCR) Is Up 10.6% After Advancing Oral Obesity Drug Into Phase 3 Trial - simplywall.stsimplywall.st · Sat, 08 Aug 2026 17:32:26 GMT Revealed: Scale of obesity drug misuse in sport - The TimesThe Times · Sat, 08 Aug 2026 11:05:47 GMT Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 22:29:17 GMT The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBCCNBC · Thu, 06 Aug 2026 13:45:29 GMT Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo - ReutersReuters · Wed, 05 Aug 2026 17:51:09 GMT Lilly and Resilience invest $750M in diabetes and obesity drug device supply - BioSpaceBioSpace · Fri, 31 Jul 2026 07:00:00 GMT Why shareholders are suing Novo Nordisk over next-generation weight-loss drug - CNBCCNBC · Wed, 29 Jul 2026 07:00:00 GMT

Timeline

Mon, 10 Aug 2026 00:24:00 GMTEli Lilly (NYSE: LLY) Files For Next-Gen Weight-Loss Drug Retatrutide In Q1 2027, Leaving Novo Nordisk (NYSE: NVO) Scrambling - foreignpolicyjournal.com

Sat, 08 Aug 2026 17:32:26 GMTStructure Therapeutics (GPCR) Is Up 10.6% After Advancing Oral Obesity Drug Into Phase 3 Trial - simplywall.st

Sat, 08 Aug 2026 11:05:47 GMTRevealed: Scale of obesity drug misuse in sport - The Times

Fri, 07 Aug 2026 22:29:17 GMTEli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion - Seeking Alpha

Thu, 06 Aug 2026 13:45:29 GMTThe divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBC

Wed, 05 Aug 2026 17:51:09 GMTLilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo - Reuters

Related explainers

PoliticsPolitics stories explain decisions, institutions, parties, leaders, laws, budgets, elections, courts, and public accountability.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.

Connected entities

Eli Lilly5 live mentions NYSE4 live mentions Novo Nordisk4 live mentions Lilly3 live mentions LLY2 live mentions Files For Next2 live mentions Gen Weight2 live mentions Loss Drug Retatrutide2 live mentions Leaving Novo Nordisk2 live mentions NVO2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Obesity Drug Into.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.